Cemex S.A.B. de C.V. Sponsored ADR vs State Street SPDR S&P Biotech ETF — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.56 (market cap $13.84B), while State Street SPDR S&P Biotech ETF trades at $149.65 (market cap $10.08B). The key difference: Cemex S.A.B. de C.V. Sponsored ADR is the larger of the two by market cap, and Cemex S.A.B. de C.V. Sponsored ADR pays a 1.3% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| CX | XBI | |
|---|---|---|
Market Cap | $13.84B | $10.08B |
Volume | 6,589,714 | 9,534,635 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $13.55 | $169.55 |
52-Week Low | $9.12 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $19.83B | — |
Dividend Yield | 1.3% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.
Read more on CX →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →